Loading...
Market
How will Caplyta's market share change by end of 2025?
3
Resolution / Starting Odds
Increases by more than 10% • 25%
Decreases by more than 10% • 25%
Remains within 10% of current share • 25%
Other • 25%
Market analysis reports from firms like IQVIA or EvaluatePharma
Story
Johnson & Johnson to Acquire Intra-Cellular Therapies for $14.6 Billion, Bolstering Neuroscience Portfolio with Caplyta
Jan 13, 2025, 12:19 PM
Johnson & Johnson has agreed to acquire Intra-Cellular Therapies for $14.6 billion in cash, or $132 per share. The deal, announced on the first day of the J.P. Morgan Healthcare Conference, aims to bolster Johnson & Johnson's neuroscience portfolio with Intra-Cellular's Caplyta, a drug approved for treating schizophrenia and bipolar depression. Intra-Cellular recently filed for an expanded approval of Caplyta to treat major depressive disorder, which could significantly increase its market potential. The acquisition also includes ITI-1284, a drug in Phase 2 testing for generalized anxiety disorder and Alzheimer's-related conditions. Johnson & Johnson plans to fund the acquisition through cash on hand and debt, with the deal expected to close later in 2025, subject to regulatory approvals.
View original story
Similar markets
No • 50%
Yes • 50%
One • 25%
None • 25%
Two • 25%
Three or more • 25%
Yes • 50%
No • 50%
5% to 10% • 25%
More than 20% • 25%
10% to 20% • 25%
Less than 5% • 25%
10% to 20% • 25%
Less than 10% • 25%
20% to 30% • 25%
More than 30% • 25%
20% to 40% • 25%
Less than 20% • 25%
More than 60% • 25%
41% to 60% • 25%
More than 30% • 25%
10% to 20% • 25%
Less than 10% • 25%
20% to 30% • 25%
40% to 60% • 25%
Less than 20% • 25%
More than 60% • 25%
20% to 40% • 25%